Acetazolamide
- Strength
- 125 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
PD-Rx Pharmaceuticals, Inc.
Acetazolamide
Listed by Gland Pharma Limited
- Strength
- 500 mg/5mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Route
- Intravenous
- Class
- Carbonic Anhydrase Inhibitor
What it contains
- Acetazolamide Sodium 500 mg/5mL
FDA record
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Drug class | Carbonic Anhydrase Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 68083-661 |
| FDA application | ANDA219775 |
| RxNorm concept | 307702 |
| Package sizes listed | 1 |
| Marketed since | June 2025 |
Other products containing Acetazolamide
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Acetazolamide
- Strength
- 250 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
PD-Rx Pharmaceuticals, Inc.
Acetazolamide
- Strength
- 250 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
Aarkish Pharmaceuticals NJ Inc.
Acetazolamide
- Strength
- 250 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
Marlex Pharmaceuticals, Inc.
Acetazolamide
- Strength
- 250 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
AvPAK
Acetazolamide
acetazolamide sodium
- Strength
- 500 mg/5mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- Carbonic Anhydrase Inhibitor
Mylan Institutional LLC
acetaZOLAMIDE
- Strength
- 125 mg/1
- Form
- Tablet
- Class
- Carbonic Anhydrase Inhibitor
Zydus Pharmaceuticals (USA) Inc.
acetazolamide
- Strength
- 500 mg/1
- Form
- Capsule
- Class
- Carbonic Anhydrase Inhibitor
Zydus Pharmaceuticals (USA) Inc.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.